While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
All entries for: Antiviral
March 5, 2026
Aligos Therapeutics
Neutral Outlook
South San Francisco, CA
51-200 employees
The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant.
Disease Area: Antiviral, Gastrointestinal, Infectious Diseases, Metabolic Diseases
Drug Type: Biologic, Small Molecule
March 4, 2026
Invivyd, Inc
Neutral Outlook
New Haven, CT
51-200 employees
The Inflation Reduction Act of 2022 (the “IRA”), among other things, permits the HHS to negotiate prescription drug prices with companies, subject to a specified cap, for Medicare units of a specified number of certain FDA approved or licensed brand name drugs or biologics without generic or biosimilar competitors each year, with such prices first set to take effect starting in 2026 for such products reimbursed under Medicare Part D and in 2028 for products reimbursed under Medicare Part B
Disease Area: Antiviral, Immune Diseases, Infectious Diseases
Drug Type: Biologic
March 2, 2026
Merck
Layoffs
Rahway, NJ
10,000+ employees
Merck is laying off 154 employees across two Durham, North Carolina facilities, following the company’s decision to stop using its Old Oxford Road facility to produce its Gardasil HPV vaccines due to declining worldwide demand.
Disease Area: Antiviral, Multiple
Drug Type: Biologic, Small Molecule
February 27, 2026
Emergent BioSolutions Inc
Negative Outlook
Gaithersburg, MD
501-1,000 employees
While we are not directly affected by the IRA at this time, these types of laws may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability.
Disease Area: Antiviral, Infectious Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Ionis Pharmaceutical
Neutral Outlook
Carlsbad, CA
1,001-5,000 employees
In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs.
Disease Area: Antiviral, Cardiology, Chronic Disease, Hematology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
February 24, 2026
Gilead Sciences - Foster City
Negative Outlook
Foster City, CA
10,000+ employees
While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 23, 2026
Vir Biotechnology, Inc.
Neutral Outlook
San Francisco, CA
201-500 employees
Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.
Disease Area: Antiviral, Chronic Disease, Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic
February 20, 2026
Moderna, Inc.
Neutral Outlook
Cambridge, MA
1,001-5,000 employees
Beginning in 2026, the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act of 2022 requires CMS to implement negotiated prices for certain high-expenditure Medicare Part D drugs. CMS has issued guidance for multiple cycles of the negotiation program, and additional negotiated pricing rounds are expected in future years. The scope, timing, and impact of this program, including its potential application to additional drugs or coverage categories, remain subject to change and could affect pricing benchmarks, reimbursement levels, and net realized prices for our products.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic